Osteoporosis is one of the most common and underdiagnosed metabolic bone diseases, affecting more than 10 million adults in the United States, with another 44 million classified as having low bone density. Nurses across every setting — primary care, hospital floors, surgical units, and long-term care — routinely care for patients who either have osteoporosis or are at high risk for it.
Fast-scan summary: key osteoporosis facts
| Parameter | Key facts |
|---|---|
| Definition | Systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, increasing fracture risk |
| Primary cause | Osteoclast activity exceeds osteoblast activity — net bone resorption exceeds formation |
| Peak bone mass age | 25–30 years; up to 90% of peak bone mass is accumulated by age 18 in females |
| DEXA T-score: normal | ≥ −1.0 |
| DEXA T-score: osteopenia | −1.0 to −2.5 |
| DEXA T-score: osteoporosis | ≤ −2.5 |
| DEXA T-score: severe osteoporosis | ≤ −2.5 plus one or more fragility fractures |
| Major risk factors | Female sex, postmenopausal estrogen loss, age >65, low BMI, White/Asian ethnicity, prior fragility fracture, long-term glucocorticoid use, family history, smoking, excessive alcohol |
| First-line medications | Bisphosphonates (alendronate, risedronate, zoledronic acid); calcium + vitamin D supplementation for all patients |
| Top nursing priorities | Fall prevention, fracture risk reduction, medication education (especially bisphosphonate administration), calcium/vitamin D optimization, home safety assessment |
Introduction
Osteoporosis is a metabolic bone disease defined by reduced bone mineral density (BMD) and deterioration of bone microarchitecture, resulting in increased susceptibility to fragility fractures — fractures occurring from low-impact trauma such as a fall from standing height or less. The disease is largely silent until a fracture occurs, earning it the label “the silent disease.”
The clinical burden is substantial. Hip fractures carry a one-year mortality rate of 20–24%, and survivors frequently experience permanent functional decline. Vertebral compression fractures — the most common osteoporotic fracture type — cause chronic pain, height loss, and kyphosis, significantly reducing quality of life. For nursing students and nurses, understanding osteoporosis means understanding pathophysiology, accurate assessment, evidence-based pharmacology, and the patient education that underpins every successful treatment plan.
Pathophysiology
Bone remodeling basics
Bone is a dynamic tissue in a continuous state of remodeling. Two cell types drive this process:
- Osteoblasts build new bone by synthesizing and mineralizing the extracellular matrix (osteoid). They are derived from mesenchymal stem cells.
- Osteoclasts resorb bone by secreting acids and proteases that dissolve mineralized matrix. They are derived from hematopoietic precursors.
In a healthy adult skeleton, osteoblast and osteoclast activity are tightly coupled — the rate of bone formation matches the rate of resorption, maintaining bone mass. This coupling begins to shift in the third to fourth decade of life, when resorption gradually outpaces formation, and bone mass slowly declines with age.
The RANK-RANKL-OPG axis
The molecular machinery governing osteoclast activation is the RANK-RANKL-OPG signaling axis, which is the mechanistic target of one major class of osteoporosis medications.
- RANKL (receptor activator of nuclear factor κB ligand) is produced by osteoblasts and stromal cells. It binds to its receptor RANK on osteoclast precursors, stimulating their differentiation and activation.
- OPG (osteoprotegerin) is a decoy receptor also produced by osteoblasts. OPG binds RANKL before it can reach RANK, thereby inhibiting osteoclast development — a natural brake on bone resorption.
- In osteoporosis, the RANKL-to-OPG ratio tilts toward RANKL dominance, resulting in excessive osteoclast activity and net bone loss.
Denosumab (Prolia) is a monoclonal antibody that mimics OPG by blocking RANKL, directly suppressing osteoclast formation. This is why denosumab is a targeted, rationally designed treatment for this pathway.
Estrogen’s role in bone
Estrogen is a critical regulator of bone remodeling in both women and men. It suppresses osteoclastogenesis by promoting OPG production and inhibiting RANKL expression. When estrogen levels fall — most dramatically at menopause — this protective effect is lost. Osteoclast activity surges, and women can lose 3–5% of trabecular bone per year in the five years following menopause. This accelerated loss is the primary driver of postmenopausal osteoporosis.
In men, estrogen (derived from testosterone via aromatization) provides similar protection. Hypogonadism in men — whether from androgen deprivation therapy, disease, or aging — also accelerates bone loss.
Calcium, vitamin D, and PTH
Calcium is the primary mineral constituent of bone. The skeleton serves as a calcium reservoir, releasing calcium into the bloodstream when dietary intake or absorption is insufficient. When serum calcium falls, the parathyroid glands secrete parathyroid hormone (PTH), which:
- Stimulates osteoclast activity to release calcium from bone
- Increases renal reabsorption of calcium
- Stimulates renal activation of vitamin D (1,25-dihydroxyvitamin D, or calcitriol), which in turn enhances intestinal calcium absorption
Chronic calcium deficiency or vitamin D deficiency therefore drives a persistent secondary hyperparathyroidism — elevated PTH continuously stimulates bone resorption to maintain serum calcium. Over years, this depletes bone mineral density even when there is no primary bone disease.
Cortical vs trabecular bone loss
Osteoporosis affects both types of bone tissue, but at different rates and in different clinical settings:
- Trabecular (cancellous) bone — the spongy, latticed bone found in vertebral bodies, the distal radius, and the femoral neck — has a much larger surface area and is metabolically much more active. It is lost more rapidly in postmenopausal women and is the primary substrate for vertebral compression fractures and wrist fractures.
- Cortical bone — the dense outer shell of long bones — is lost more slowly but accounts for 80% of the total skeleton. Age-related cortical bone loss drives hip fracture risk, which increases dramatically after age 70.
Understanding this distinction explains why vertebral fractures tend to appear earlier in the postmenopausal period, while hip fractures peak in the eighth and ninth decades of life.
Risk factors
Osteoporosis risk factors are typically divided into non-modifiable and modifiable categories. The WHO FRAX tool (Fracture Risk Assessment Tool) integrates these factors to calculate a patient’s 10-year probability of a major osteoporotic fracture or hip fracture specifically — providing a clinically actionable risk score that guides treatment decisions.
| Category | Risk factor | Clinical notes |
|---|---|---|
| Non-modifiable | Female sex | Women have lower peak bone mass and estrogen-dependent accelerated loss at menopause |
| Age >65 (women), >70 (men) | USPSTF recommends routine DXA screening at these ages | |
| White or Asian ethnicity | Lower peak bone mass in these groups compared to Black Americans | |
| Family history of osteoporosis or hip fracture | Strong genetic component; parental hip fracture is a FRAX input | |
| Prior fragility fracture | Single strongest predictor of future fracture — doubles the risk | |
| Postmenopause (especially early/surgical) | Surgical menopause before age 45 significantly increases lifetime risk | |
| Rheumatoid arthritis | Inflammatory cytokines (TNF-α, IL-6) increase osteoclast activity via RANK-RANKL signaling; long-term corticosteroid use compounds bone loss. See rheumatoid arthritis nursing reference for full management details. | |
| Modifiable | Glucocorticoid use (≥5 mg prednisone/day for ≥3 months) | Most common cause of secondary osteoporosis; impairs osteoblast function |
| Low BMI (<18.5 kg/m²) | Less mechanical loading on bone; lower fat-derived estrogen postmenopause | |
| Smoking | Reduces osteoblast activity; smokers reach menopause ~2 years earlier | |
| Excessive alcohol (>3 units/day) | Direct osteoblast toxicity; also increases fall risk | |
| Calcium and vitamin D deficiency | Drives secondary hyperparathyroidism and accelerated bone resorption | |
| Physical inactivity / prolonged immobility | Weight-bearing mechanical stress is a primary stimulus for bone formation | |
| Secondary causes | Celiac disease, hyperthyroidism, hyperparathyroidism, hypogonadism, renal disease, malabsorption syndromes, anticonvulsants, proton pump inhibitors (long-term) |
Clinical presentation
One of the most clinically important facts about osteoporosis is that it produces no symptoms until a fracture occurs. Patients do not feel their bones weakening. This means nurses must recognize the indirect signs and risk patterns that point toward undiagnosed disease.
The silent phase
Osteoporosis is asymptomatic for years to decades. The first clinical event is often a fracture. Vertebral compression fractures may even be asymptomatic, discovered incidentally on chest X-ray or CT scan ordered for another reason.
Vertebral compression fractures
Vertebral compression fractures (VCFs) are the most common osteoporotic fractures, occurring predominantly in the mid-thoracic (T6–T8) and thoracolumbar junction (T12–L1) regions. Clinical features include:
- Acute back pain, often sudden-onset, after minimal exertion (lifting, bending, coughing)
- Chronic back pain from multiple healed fractures
- Progressive loss of height — each VCF causes approximately 1–2 cm of height loss; multiple fractures can cause 4–6 inches of total height reduction
- Kyphosis (Dowager’s hump) — thoracic kyphosis from collapsed vertebral bodies; characteristic progressive forward curvature of the spine
- Reduced lung volumes from thoracic cage compression
- Abdominal protrusion and early satiety as the rib cage descends toward the pelvis
- Radiculopathy if a collapsed vertebra compresses a nerve root
Hip fractures
Hip fractures (femoral neck and intertrochanteric) are the most clinically devastating osteoporotic fractures. They almost always require surgical repair (ORIF or arthroplasty) and carry a 20–24% one-year mortality rate. Survivors frequently experience permanent loss of independence, with up to 50% never returning to their prior level of ambulation.
Wrist fractures
Colles’ fractures of the distal radius are common in the early postmenopausal period and often occur when a patient falls and attempts to catch themselves. They are a warning sign warranting bone density evaluation.
DEXA scan and T-scores
Dual-energy X-ray absorptiometry (DEXA or DXA) is the gold standard for measuring bone mineral density (BMD). The scan is painless, takes 10–20 minutes, and uses very low radiation doses. It measures BMD at the lumbar spine (L1–L4) and proximal femur (femoral neck and total hip), which are the standard reporting sites.
T-score interpretation
The T-score compares a patient’s BMD to the peak bone mass of a healthy 30-year-old adult of the same sex (the reference population). Each unit is one standard deviation.
| T-score range | Diagnosis | Clinical implication |
|---|---|---|
| ≥ −1.0 | Normal bone density | Routine monitoring per age/risk guidelines |
| −1.0 to −2.5 | Osteopenia (low bone mass) | Lifestyle interventions; consider pharmacotherapy if FRAX 10-year major fracture risk ≥20% or hip fracture risk ≥3% |
| ≤ −2.5 | Osteoporosis | Pharmacotherapy indicated; calcium + vitamin D supplementation; fall prevention |
| ≤ −2.5 plus ≥1 fragility fracture | Severe (established) osteoporosis | Urgent pharmacotherapy; consider anabolic agents for very high fracture risk |
Z-scores
The Z-score compares the patient’s BMD to age-matched and sex-matched peers, rather than to peak young-adult bone mass. Z-scores are used in premenopausal women, men under 50, and children. A Z-score ≤ −2.0 suggests BMD that is lower than expected for age and prompts evaluation for secondary causes of bone loss.
FRAX integration
T-score alone does not fully capture fracture risk, because fall risk, prior fracture history, and other clinical variables are equally important. The FRAX tool (available at www.sheffield.ac.uk/FRAX) incorporates age, sex, BMI, prior fracture, parental hip fracture, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis causes to produce a 10-year probability for major osteoporotic fracture and hip fracture. FRAX inputs can include or exclude BMD. Treatment thresholds in the US (National Osteoporosis Foundation): major fracture ≥20% or hip fracture ≥3%.
Laboratory findings
Labs in osteoporosis serve primarily to identify secondary causes and assess metabolic bone status. Uncomplicated postmenopausal osteoporosis typically produces normal serum chemistry — abnormal labs suggest a secondary cause requiring separate treatment.
| Lab test | Reference range (adult) | Significance in osteoporosis workup |
|---|---|---|
| Serum calcium | 8.5–10.5 mg/dL | Usually normal in primary osteoporosis. Hypercalcemia → hyperparathyroidism or malignancy. Hypocalcemia → vitamin D deficiency, malabsorption. Always correct for albumin; see electrolyte imbalances nursing. |
| Serum phosphate | 2.5–4.5 mg/dL | Low phosphate → malnutrition, malabsorption, X-linked hypophosphatemia. Elevated in renal failure. Normal in most primary osteoporosis cases. See electrolyte imbalances nursing. |
| 25-OH vitamin D (calcidiol) | Goal >30 ng/mL (>75 nmol/L) | Most useful vitamin D test for assessing body stores. Levels <20 ng/mL = deficiency requiring aggressive repletion. Levels 20–30 ng/mL = insufficiency. Deficiency drives secondary hyperparathyroidism and bone loss. Check via nursing lab values cheat sheet. |
| 1,25-OH vitamin D (calcitriol) | 18–72 pg/mL | Active form; synthesized in kidney. Useful when renal osteodystrophy or granulomatous disease (sarcoid, TB) is suspected. Not the primary screening test for vitamin D deficiency. |
| PTH (intact) | 10–65 pg/mL | Elevated in vitamin D deficiency and calcium deficiency (secondary hyperparathyroidism) — bone loss accelerator. Also elevated in primary hyperparathyroidism. Suppressed in hypercalcemia from malignancy (PTHrP-mediated). |
| Alkaline phosphatase (ALP) | 44–147 U/L (adult) | Marker of osteoblast activity. Elevated in Paget's disease, healing fracture, primary hyperparathyroidism, osteomalacia. Usually normal or mildly elevated in osteoporosis. |
| Bone-specific ALP (BSALP) | 11.6–29.6 U/L (postmenopausal women) | More specific marker of osteoblast activity than total ALP. Useful for monitoring anabolic therapy response (teriparatide, romosozumab). |
| Osteocalcin | 11–48 ng/mL | Protein produced by osteoblasts; marker of bone formation. Elevated states indicate increased bone turnover. Used in research and specialized monitoring contexts. |
| NTX (N-telopeptide) / CTX (C-telopeptide) | NTX: 5–65 nmol BCE/mmol Cr (urine) CTX: <573 pg/mL (serum, postmenopausal) |
Bone resorption markers. Derived from collagen breakdown during osteoclast activity. Elevated values confirm high bone turnover and help monitor antiresorptive therapy response. CTX is commonly used to assess resorption suppression with bisphosphonates. |
| CBC | WBC 4,500–11,000/µL, Hgb 12–17 g/dL, Plt 150,000–400,000/µL | Screens for hematologic malignancy (multiple myeloma) as a cause of bone loss. Multiple myeloma produces osteolytic lesions with elevated calcium. Also establishes baseline before initiating denosumab (risk of severe hypocalcemia). |
| Comprehensive metabolic panel (CMP) | Per individual component references | Renal function (creatinine, eGFR) critical before prescribing bisphosphonates (contraindicated if eGFR <30–35 mL/min/1.73m²). Hepatic function relevant for all pharmacotherapy. Sodium, potassium baseline. See nursing lab values cheat sheet. |
| Thyroid function (TSH) | TSH: 0.4–4.0 mIU/L | Hyperthyroidism and excessive thyroid hormone replacement increase bone turnover. Screen in all patients with unexplained bone loss. |
Nursing assessment
A thorough nursing assessment for osteoporosis addresses bone health, fracture risk, fall risk, functional status, and patient safety — both in the hospital and at home.
Height and weight
Serial height measurement is the simplest clinical indicator of vertebral compression fractures. A loss of more than 1.5 inches (3.8 cm) from maximum adult height, or more than 0.8 inches (2 cm) since last visit, warrants spinal X-ray evaluation. Weigh the patient to calculate BMI — low BMI is an independent fracture risk factor.
Fall risk assessment
Because most fractures result from falls, fall risk assessment is central to osteoporosis nursing care. Two validated tools are used commonly:
- Morse Fall Scale — assesses history of falling, secondary diagnosis, ambulatory aid use, IV line, gait, and mental status; score ≥45 = high fall risk
- STRATIFY (St. Thomas’s Risk Assessment Tool in Falling Elderly Inpatients) — five-item binary tool for inpatient use
In primary care, the CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit provides a structured approach to community fall risk, including the Timed Up and Go (TUG) test — normal TUG ≤12 seconds; ≥12 seconds indicates fall risk.
This overlaps with content in the head-to-toe nursing assessment framework, where functional status, gait, and balance are evaluated systematically.
Kyphosis and posture assessment
Observe the patient from the side. Progressive thoracic kyphosis, loss of lumbar lordosis, and forward head posture are visible signs of multiple vertebral compression fractures. Document any visible spinal deformity and compare to prior assessments.
Pain assessment
Use a structured pain assessment tool (NRS 0–10, OLDCARTS framework). Characterize:
- Location and radiation
- Association with movement vs rest
- Acute vs chronic onset
- Prior fracture history
Functional assessment and ADLs
Determine the patient’s ability to perform instrumental ADLs (cooking, housekeeping, shopping) and basic ADLs (bathing, dressing, toileting). Osteoporotic fractures often trigger sudden functional decline, particularly in older adults.
Medication review
Conduct a thorough medication reconciliation. Identify:
- Bone-depleting medications: glucocorticoids (most significant), proton pump inhibitors (long-term), anticonvulsants (phenytoin, phenobarbital), anticoagulants, aromatase inhibitors, androgen deprivation therapy, excess thyroid hormone
- Fall-risk medications: sedatives, hypnotics, antidepressants, antipsychotics, antihypertensives causing orthostatic hypotension, opioids, benzodiazepines
Polypharmacy is a major fall risk factor. Review using the Beers Criteria for potentially inappropriate medications in older adults.
Nursing interventions
| Nursing problem | Interventions | Rationale |
|---|---|---|
| Risk for falls | Implement fall precautions (bed in lowest position, brakes locked, call light within reach); nonskid footwear; bed alarm; remove floor clutter; ensure adequate room lighting; hourly rounding; assess orthostatic blood pressure; review fall-risk medications | Osteoporotic bones fracture from low-impact falls. Fall prevention is the highest-priority intervention to prevent fracture-related morbidity and mortality |
| Risk for fracture | Assist with ambulation and transfers; use gait belt; do not rush; avoid side rails for patient pushing up in bed; position call light within reach; educate on fall reporting | Fragile bones fracture under minimal mechanical stress. Safe mobility assistance reduces fracture events in hospital and long-term care settings |
| Acute/chronic pain | Administer analgesia per order (acetaminophen first-line for chronic VCF pain; NSAIDs with caution in elderly/renal disease; calcitonin nasal spray may provide modest acute VCF pain relief); position with log-roll technique; apply heat for chronic back pain; encourage gentle movement within pain tolerance | Vertebral compression fractures produce periosteal stretch and muscle spasm. Pain control supports mobility and reduces immobilization-related bone loss |
| Knowledge deficit: disease, medications, and self-care | Educate on osteoporosis pathophysiology, fracture risk, and the importance of medication adherence; teach correct bisphosphonate administration technique; provide written materials; involve family/caregivers; assess health literacy | Osteoporosis is often perceived as a "normal" consequence of aging — many patients do not understand it is a treatable disease or that medication adherence determines fracture reduction |
| Impaired physical mobility | Encourage weight-bearing activity as tolerated (walking, gentle strength training); collaborate with physical therapy for individualized exercise prescription; address pain barriers to mobility | Weight-bearing mechanical loading stimulates osteoblast activity and preserves bone mass. Immobility accelerates bone loss and increases fall and fracture risk |
| Imbalanced nutrition: calcium and vitamin D | Assess dietary calcium intake; counsel on calcium-rich foods; recommend supplementation as appropriate; ensure adequate vitamin D through diet, supplementation, and safe sun exposure; monitor 25-OH vitamin D levels | Adequate calcium (1,000–1,200 mg/day) and vitamin D (goal 25-OH-D >30 ng/mL) are required substrates for bone mineralization. Deficiency drives secondary hyperparathyroidism and bone loss even with pharmacotherapy |
| Medication non-adherence | Review and simplify medication regimen; educate on the mechanism and long-term benefits of bisphosphonates; address side effect concerns; schedule follow-up DXA; use once-weekly oral formulations or annual IV infusion when daily adherence is problematic | Bisphosphonate therapy reduces vertebral fracture risk by 40–70% and hip fracture risk by 40–50% — but only with consistent use. Adherence rates for daily oral bisphosphonates drop sharply within the first year |
| Risk for ADL deficit post-fracture | Involve occupational therapy for adaptive equipment assessment; arrange home safety evaluation; discuss rehabilitation goals; assess caregiver support; refer for home health services post-discharge | Hip and vertebral fractures frequently precipitate functional decline requiring long-term support. Early OT and PT involvement improves functional recovery and reduces re-hospitalization |
| Risk for infection (post-fracture surgical patient) | Monitor surgical wound; assess for signs of infection; maintain aseptic technique with dressing changes; monitor CBC and fever; ensure perioperative antibiotic prophylaxis per protocol | Older adults undergoing hip or vertebral fracture repair have heightened infection risk due to immunosenescence, nutritional deficits, and prolonged immobility |
Medications for osteoporosis
Pharmacotherapy is initiated when T-score ≤ −2.5, when severe osteoporosis (T-score ≤ −2.5 plus fragility fracture) is present, or when osteopenia exists alongside a FRAX 10-year risk of ≥20% for major fracture or ≥3% for hip fracture. All patients receiving pharmacotherapy should also receive adequate calcium and vitamin D supplementation.
See the medication rights in nursing framework for general medication safety principles when administering these agents.
| Drug (brand name) | Class / mechanism | Route / frequency | Key nursing considerations |
|---|---|---|---|
| Alendronate (Fosamax) | Bisphosphonate — inhibits farnesyl pyrophosphate synthase in osteoclasts, inducing osteoclast apoptosis and suppressing bone resorption | Oral; 70 mg once weekly (or 10 mg daily) | Take on empty stomach with 6–8 oz plain water; 30–60 min before first food, drink (other than water), or medication of the day; remain upright (sit or stand) for 30–60 min after taking to prevent esophageal irritation/ulceration. Contraindicated in esophageal abnormalities and if patient cannot remain upright. Caution if eGFR <35 mL/min. |
| Risedronate (Actonel) | Bisphosphonate — same mechanism as alendronate; slightly less GI irritation reported | Oral; 35 mg once weekly, 75 mg on two consecutive days/month, or 150 mg once monthly | Same administration protocol as alendronate: empty stomach, upright position 30 min post-dose. May cause esophageal irritation, GI upset, musculoskeletal pain. Monitor eGFR. |
| Zoledronic acid (Reclast) | Bisphosphonate — IV formulation; most potent bisphosphonate; single infusion provides 12 months of antiresorptive effect | IV; 5 mg infusion once yearly | Ensure adequate hydration before and after infusion to reduce acute-phase reaction (fever, myalgia, flu-like symptoms in ~30% of first-dose patients). Contraindicated if eGFR <35 mL/min. Rare risks: osteonecrosis of the jaw (ONJ), atypical femoral fracture with long-term use. Preferred when oral adherence is poor or GI intolerance is present. |
| Raloxifene (Evista) | Selective estrogen receptor modulator (SERM) — estrogen agonist in bone (inhibits bone resorption), estrogen antagonist in breast and uterus | Oral; 60 mg daily | Reduces vertebral fracture risk; does NOT reduce hip fracture risk. Also reduces breast cancer risk (used in chemoprevention). Contraindicated in women with active or past DVT/PE — increases VTE risk (approximately 3-fold). Hot flashes are a common side effect. Discontinue 72 hours before prolonged immobilization (surgery, travel). See DVT nursing for anticoagulation context. |
| Teriparatide (Forteo) | Recombinant human PTH 1-34 — anabolic agent; stimulates osteoblast proliferation and activity, increasing bone formation (intermittent PTH stimulates formation; continuous stimulates resorption) | Subcutaneous injection; 20 mcg daily; max 2 years cumulative | Black box warning: osteosarcoma risk in animal studies (rat models at very high doses); contraindicated in patients with prior radiation therapy to the skeleton, Paget's disease, unexplained ALP elevation, or those at increased risk for osteosarcoma. Monitor serum calcium (may cause transient hypercalcemia). Refrigerate; discard 28 days after first use. Must be followed by antiresorptive therapy after discontinuation to preserve gains. |
| Romosozumab (Evenity) | Sclerostin inhibitor — dual mechanism: anabolic (promotes osteoblast activity by blocking sclerostin-mediated inhibition of Wnt signaling) AND antiresorptive (reduces RANKL); provides rapid BMD gains | Subcutaneous injection; 210 mg (two 105 mg injections) once monthly; 12-month treatment limit | Cardiovascular warning: increased risk of myocardial infarction, stroke, and cardiovascular death — contraindicated in patients with MI or stroke in the preceding year. After the 12-month course, must transition to antiresorptive therapy. Monitor for injection-site reactions, arthralgia. |
| Denosumab (Prolia) | RANKL inhibitor (monoclonal antibody) — binds RANKL, preventing osteoclast formation and activation; mimics the natural OPG mechanism | Subcutaneous injection; 60 mg every 6 months | Do NOT stop abruptly — discontinuation causes rapid rebound increase in bone resorption, with multiple vertebral fractures reported within 7–12 months of stopping. If discontinuing, must transition to bisphosphonate therapy to protect against rebound. Check serum calcium and vitamin D before each dose — hypocalcemia is a serious risk (ensure adequate calcium and vitamin D supplementation). Monitor for injection-site reactions, infection risk (inhibition of RANKL has immune effects). Can be used in severe renal failure (unlike bisphosphonates). |
| Calcium supplementation | Nutritional supplement — provides substrate for bone mineralization; prevents secondary hyperparathyroidism-driven bone resorption | Oral; split doses ≤500 mg for optimal absorption | Postmenopausal women: 1,200 mg/day total (diet + supplement). Adults ages 19–50: 1,000 mg/day. Do not exceed 2,500 mg/day. Calcium carbonate: requires gastric acid for absorption — take with food; higher elemental calcium per tablet (40%). Calcium citrate: acid-independent absorption — can take without food; preferred in patients on PPIs, achlorhydria, or with gastric bypass. Caution in patients with CKD (risk of vascular calcification; phosphate binders may be used instead). |
| Vitamin D supplementation | Fat-soluble vitamin — promotes intestinal calcium absorption; essential co-factor for bone mineralization; deficiency drives PTH-mediated bone resorption | Oral; typically vitamin D₃ (cholecalciferol) 800–2,000 IU daily | Goal serum 25-OH vitamin D >30 ng/mL (>75 nmol/L). Deficiency (<20 ng/mL) requires repletion doses (50,000 IU weekly for 8–12 weeks, then maintenance). Monitor 25-OH-D levels every 3–6 months during repletion, then annually. Toxicity possible at very high doses (>10,000 IU/day prolonged) — symptoms of hypercalcemia. |
Fall prevention
Fall prevention is the single most impactful nursing intervention in osteoporosis care. Every fracture avoided is a potential hip surgery, hospitalization, and functional decline averted.
Hospital fall prevention protocol
In the hospital setting, implement a systematic fall prevention bundle for any patient with known or suspected osteoporosis:
- Environment: bed in lowest locked position; call light within reach; bed alarm activated; pathway clear to bathroom; nonskid socks
- Toileting assistance: proactive hourly rounding and toileting offers, especially at night; identify patients who may resist asking for help
- Lighting: ensure adequate lighting in room and bathroom; nightlight as needed
- Footwear: hospital socks with grips; encourage patients to bring their own well-fitting nonskid footwear
- Orthostatic hypotension: check blood pressure lying, sitting, and standing; hold antihypertensives as clinically appropriate; instruct patients to dangle legs before standing
- Medication reconciliation: flag all sedating medications — benzodiazepines, opioids, sleep aids, antidepressants, first-generation antihistamines, antipsychotics — for provider review; these are Beers Criteria medications in older adults
Community fall prevention
For patients being discharged or seen in outpatient settings, the following home safety assessment is part of comprehensive osteoporosis nursing care:
Inside the home:
- Remove throw rugs and clutter from walking paths
- Install grab bars in bathroom (beside toilet and in shower/tub)
- Use shower chair and handheld shower head
- Ensure adequate lighting on stairs and hallways; install nightlights
- Move frequently used items to accessible height to avoid reaching and bending
Exercise:
- Weight-bearing aerobic exercise (walking, low-impact aerobics) 3–5 times per week
- Resistance/strength training 2–3 times per week, focusing on lower extremities
- Balance training (Tai Chi has the strongest evidence for fall reduction; yoga, balance exercises)
- Refer to physical therapy for formal fall prevention and balance program
Vision:
- Annual vision examination; update corrective lenses
- Caution with bifocals and progressive lenses on stairs
Footwear:
- Properly fitting, low-heeled shoes with nonskid soles
- Avoid walking in socks alone, slippers without backing, or high heels
Medications and falls
Prescribing cascades and polypharmacy significantly increase fall risk. Key drug categories the nurse should flag:
- Sedative-hypnotics (benzodiazepines, non-benzo sleep aids): impair psychomotor function and coordination
- Opioid analgesics: sedation and orthostatic effects
- Antidepressants (especially SSRIs, TCAs): orthostatic hypotension, sedation
- Antihypertensives and diuretics: volume depletion, orthostatic hypotension
- Anticholinergics: confusion, blurred vision, balance disruption
Patient education
Effective patient education for osteoporosis is multidimensional and must address diet, lifestyle, medication use, and home safety. Assess health literacy before beginning — use plain language and teach-back to confirm understanding.
Calcium-rich foods
Dietary calcium is preferable to supplemental calcium and carries no cardiovascular risk concerns. Coach patients on common high-calcium foods:
- Dairy: milk (300 mg/cup), plain yogurt (415 mg/cup), cheese (200–300 mg/slice)
- Fortified foods: calcium-fortified orange juice, soy milk, cereals
- Leafy greens: kale (94 mg/cup cooked), bok choy, broccoli; note that spinach and beet greens contain oxalates that impair calcium absorption
- Canned fish with soft bones: sardines (325 mg/serving), canned salmon (180 mg/serving)
- Fortified tofu
Total dietary calcium goal: 1,000 mg/day for adults 19–50; 1,200 mg/day for postmenopausal women and men over 70.
Vitamin D sources
Vitamin D₃ is synthesized in the skin via UVB exposure and is found in limited dietary sources:
- Fatty fish: salmon (570–800 IU/serving), tuna, mackerel
- Fortified foods: vitamin D-fortified milk (100 IU/cup), fortified cereals, orange juice
- Egg yolks (41 IU each)
- Most patients require supplementation to reach 25-OH-D levels above 30 ng/mL, particularly in northern latitudes, during winter months, and in patients who use sunscreen consistently or spend little time outdoors
Exercise
Explain to patients that weight-bearing exercise is not dangerous — it is protective. Bone responds to mechanical loading by building mass. Patients who fear activity because of osteoporosis risk becoming more sedentary, accelerating bone loss and fall risk. Walking 30 minutes daily is an accessible, effective starting point. Resistance training builds muscle, improves balance, and directly stimulates bone formation.
Swimming and cycling are excellent cardiovascular exercise but do not provide bone-building mechanical loading.
Bisphosphonate administration — key teaching points
Incorrect bisphosphonate administration is one of the most common sources of esophageal side effects and medication discontinuation. Teach the following clearly:
- Take on an empty stomach (nothing by mouth overnight before)
- Swallow with a full glass (6–8 oz) of plain water only — no juice, coffee, tea, or other liquids
- Do not eat, drink anything other than plain water, or take any other medication for 30–60 minutes after taking the dose
- Remain upright (sitting or standing) for 30–60 minutes after taking — do not lie down
- If a dose is missed on the scheduled day of the week, take it the next morning — do not double-dose
- Esophageal symptoms (burning, chest pain, difficulty swallowing) should be reported immediately; do not take another dose until evaluated
These instructions exist because bisphosphonates are highly caustic to esophageal mucosa if they contact it. Staying upright and maintaining an empty stomach prevents prolonged esophageal contact.
Lifestyle modifications
- Smoking cessation: smoking reduces osteoblast activity and accelerates bone loss by approximately 0.5% per year additional vs non-smokers. Refer to cessation resources.
- Alcohol reduction: limit to ≤1 drink/day for women, ≤2 drinks/day for men. Excessive alcohol directly damages osteoblasts.
- Fall hazard awareness: coach on home safety (see fall prevention section above)
- Consistent medication use: emphasize that bisphosphonates work slowly — 12–24 months to show significant DXA improvement. Discontinuation within the first year eliminates the benefit.
Fracture complications and nursing care
Hip fracture
Hip fractures in patients with osteoporosis represent a nursing-intensive perioperative and rehabilitation challenge. The head-to-toe nursing assessment provides a useful framework for systematic perioperative monitoring.
Perioperative nursing care:
- Vital signs and hemodynamic monitoring — hip fractures involve significant blood loss and risk of hemodynamic instability
- Pain management — adequate analgesia is essential; undertreated pain delays early mobilization
- Neurovascular checks distal to the fracture site: assess the 5 Ps — Pain, Pulse, Paresthesia, Pallor, Paralysis (Poikilothermia) — every 1–4 hours; changes may indicate vascular compromise, compartment syndrome, or nerve injury. This assessment follows the same principles outlined in the head-to-toe nursing assessment
- Positioning per surgical protocol (especially after total hip arthroplasty: hip precautions — no flexion beyond 90°, no adduction past midline, no internal rotation, depending on surgical approach)
- Skin integrity: pressure injury prevention with repositioning every 2 hours; heel offloading
DVT prophylaxis: Hip fractures carry extremely high DVT and PE risk — estimated 40–60% rate of proximal DVT without prophylaxis. See DVT nursing for a full discussion of DVT prevention and management. Pharmacologic prophylaxis (LMWH, fondaparinux, direct oral anticoagulants, or warfarin per protocol) should begin within 12–24 hours of surgery unless contraindicated. Mechanical prophylaxis (sequential compression devices, compression stockings) should be used from admission. Early ambulation — typically day of or day after surgery — is the most effective combined measure.
Delirium prevention: Older adults with hip fractures are at extremely high risk for postoperative delirium. Use the HELP (Hospital Elder Life Program) protocol: adequate sleep, early mobilization, nutrition and hydration, cognitive stimulation, hearing and vision correction. Avoid Foley catheters beyond 24 hours. Minimize sedating medications.
Vertebral compression fracture
Management of acute VCF focuses on pain control, spinal stability, and preventing additional fractures:
- Positioning: log-roll technique for turning to prevent rotational stress on fractured vertebra; head of bed elevation ≤30° for comfort
- Back brace: thoracolumbosacral orthosis (TLSO) may be prescribed for unstable fractures or significant pain — assist with application, ensure proper fit, monitor skin integrity beneath brace
- Pain management: acetaminophen first-line; calcitonin nasal spray (Miacalcin, 200 IU daily, alternating nostrils) may reduce acute VCF pain by a modest amount; NSAIDs with caution (GI and renal risks in elderly); opioids for severe acute pain with monitoring
- Activity: encourage gradual mobilization as tolerated; complete bed rest worsens bone loss and increases complication risk
Wrist (Colles’) fracture
Wrist fractures in osteoporotic patients are typically managed with cast immobilization or surgical fixation. Nursing care includes monitoring neurovascular status of the affected hand, cast care education, and ensuring the fracture triggers appropriate osteoporosis workup — many patients sustain wrist fractures years before hip or vertebral fractures and are never assessed for underlying bone disease.
Comparison: osteoporosis vs osteomalacia vs osteoarthritis
These three conditions are frequently confused by nursing students and on the NCLEX. Understanding their differences is essential for clinical reasoning.
| Feature | Osteoporosis | Osteomalacia | Osteoarthritis |
|---|---|---|---|
| Pathophysiology | Adequate bone mineralization but reduced bone quantity; osteoclast activity exceeds osteoblast activity | Failure of bone mineralization — osteoid matrix is produced but not calcified; most often due to severe vitamin D deficiency | Degenerative joint disease — cartilage breakdown and subchondral bone changes; bone density may be normal or elevated |
| Key cause | Estrogen deficiency, aging, glucocorticoids, calcium/vitamin D deficiency | Severe vitamin D deficiency, malabsorption, renal failure, phosphate wasting | Aging, joint overuse, obesity, joint injury, genetics |
| DEXA T-score | ≤ −2.5 for osteoporosis diagnosis | May show low BMD, but DXA is not the diagnostic tool; bone biopsy is gold standard | DXA typically normal to elevated; not useful for OA diagnosis |
| Laboratory findings | Usually normal calcium, phosphate, ALP. Low 25-OH vitamin D possible; elevated PTH in secondary hyperparathyroidism variant | Low calcium, low phosphate, elevated ALP, low 25-OH vitamin D, elevated PTH, low urine calcium | Labs typically normal; may have mild inflammatory markers with inflammatory arthritis overlap |
| Symptoms | Silent until fracture; back pain from VCF, kyphosis, height loss | Diffuse bone pain and tenderness, proximal muscle weakness, waddling gait, pseudofractures (Looser zones on X-ray) | Joint pain worsening with use, morning stiffness <30 min, crepitus, bony enlargement, reduced range of motion |
| Treatment focus | Bisphosphonates, denosumab, anabolic agents; calcium + vitamin D; fall prevention | High-dose vitamin D repletion and calcium supplementation; treat underlying cause | Weight management, physical therapy, NSAIDs, intra-articular injections, joint replacement |
NCLEX-style practice questions
Question 1
A nurse is providing discharge instructions to a 68-year-old postmenopausal woman beginning alendronate (Fosamax) 70 mg weekly. Which instruction is most important to include?
A. Take the medication with a full glass of milk for best absorption B. Take the medication immediately upon waking, remain upright for 30–60 minutes, and do not eat or drink anything except plain water for 30–60 minutes C. Take the medication with your morning vitamins and breakfast to prevent nausea D. Take the medication at bedtime so you can lie down comfortably afterward
Correct answer: B
Rationale: Bisphosphonates such as alendronate are caustic to the esophageal mucosa. To prevent esophageal irritation and ulceration, the medication must be taken on an empty stomach with 6–8 oz of plain water only, and the patient must remain upright (sitting or standing) for 30–60 minutes afterward. Option A is incorrect — milk (calcium) would bind to the medication and impair its absorption. Option C is incorrect — food and other beverages impair absorption and increase esophageal contact time. Option D is incorrect — lying down after taking a bisphosphonate markedly increases the risk of esophageal injury.
Question 2
A nurse is admitting an 82-year-old woman with a hip fracture. Which intervention takes highest priority?
A. Scheduling a DEXA scan to evaluate bone mineral density B. Initiating sequential compression devices and assessing for DVT risk C. Completing an intake dietary history to assess calcium and vitamin D D. Teaching the patient about bisphosphonate therapy
Correct answer: B
Rationale: Using Maslow’s hierarchy, physiological safety takes precedence. Hip fracture carries a 40–60% rate of DVT without prophylaxis, and DVT can lead to fatal pulmonary embolism — an immediate life-threatening complication. Initiating mechanical DVT prophylaxis addresses the most urgent physiological risk. Options A, C, and D are important but represent lower-priority secondary concerns in the acute setting. See DVT nursing for full DVT assessment and prevention content.
Question 3
A patient’s DEXA report shows a lumbar spine T-score of −2.7. The nurse correctly interprets this as:
A. Normal bone density within one standard deviation of the young adult mean B. Osteopenia indicating low bone mass but not diagnostic of osteoporosis C. Osteoporosis, as the T-score is ≤ −2.5 D. The result is uninterpretable without knowing the patient’s age and Z-score
Correct answer: C
Rationale: A T-score ≤ −2.5 meets the WHO diagnostic criterion for osteoporosis. The T-score compares the patient’s bone mineral density to the peak bone mass of a healthy young adult; each unit represents one standard deviation below that reference. A T-score of −2.7 indicates that this patient’s BMD is 2.7 standard deviations below peak young-adult bone mass. Option A is incorrect — normal is T-score ≥ −1.0. Option B is incorrect — osteopenia is T-score −1.0 to −2.5. Option D is incorrect — the T-score alone is sufficient for diagnosis in postmenopausal women and men ≥50; the Z-score is used for premenopausal women and men <50.
Question 4
A nurse is caring for a patient with stage 4 chronic kidney disease (eGFR 22 mL/min/1.73m²) and osteoporosis. The provider is considering pharmacotherapy. Which medication is the nurse most likely to question?
A. Denosumab (Prolia) 60 mg SC every 6 months B. Alendronate (Fosamax) 70 mg PO weekly C. Calcium citrate 500 mg PO twice daily D. Vitamin D₃ 1,000 IU PO daily
Correct answer: B
Rationale: Bisphosphonates are contraindicated when eGFR <30–35 mL/min/1.73m², as they are renally cleared and can accumulate to toxic levels in severe renal impairment, risking adynamic bone disease and further renal injury. With an eGFR of 22, alendronate is contraindicated. Denosumab (option A) can be used in severe renal impairment and does not require dose adjustment; however, hypocalcemia risk is heightened in CKD and must be carefully managed. Calcium citrate (option C) is preferred over calcium carbonate in CKD patients (who often have achlorhydria and use PPIs), though doses must be managed carefully to avoid hypercalcemia and vascular calcification. Vitamin D supplementation (option D) is appropriate but may require activated forms (calcitriol) in advanced CKD where the kidney cannot adequately convert 25-OH-D.
Question 5
A patient is prescribed teriparatide (Forteo) for severe osteoporosis. Which information is most important for the nurse to include in teaching?
A. Teriparatide prevents bone resorption by blocking osteoclast activity at the RANKL receptor B. Teriparatide is a daily subcutaneous injection that must be refrigerated and can be used long-term without restrictions C. Teriparatide stimulates new bone formation through osteoblast activation; there is a black box warning for osteosarcoma, and treatment is limited to a cumulative maximum of 2 years D. Teriparatide can be taken orally once weekly with a full glass of water on an empty stomach
Correct answer: C
Rationale: Teriparatide is a recombinant human PTH (1-34) fragment that works by intermittently stimulating osteoblasts — the bone-building cells — making it an anabolic (bone-forming) agent, unlike antiresorptive agents that primarily suppress osteoclasts. The FDA issued a black box warning based on osteosarcoma development in rat models at high doses; teriparatide is therefore limited to a cumulative lifetime maximum of 2 years. Option A is incorrect — RANKL inhibition describes denosumab’s mechanism, not teriparatide. Option B is incorrect — while teriparatide is a daily SC injection requiring refrigeration, it carries a 2-year lifetime treatment limit. Option D is incorrect — teriparatide is subcutaneous, not oral.
Question 6
A patient receiving denosumab (Prolia) 60 mg SC every 6 months decides to stop taking the medication without consulting her provider. Which complication does the nurse identify as the primary risk?
A. Hypercalcemia from unchecked osteoclast activity rebound B. Multiple vertebral compression fractures from rapid rebound bone resorption following discontinuation C. Osteonecrosis of the jaw, which is most severe after abrupt discontinuation D. Esophageal erosions from denosumab withdrawal syndrome
Correct answer: B
Rationale: Abrupt discontinuation of denosumab is a serious and well-documented clinical hazard. When denosumab is stopped, the RANKL-blocking effect rapidly dissipates, leading to a dramatic rebound in osteoclast activity — in some cases exceeding pre-treatment resorption rates. Multiple vertebral compression fractures have been reported in the 7–12 months following abrupt discontinuation. Patients should always transition to bisphosphonate therapy upon stopping denosumab. Option A is partially plausible but not the primary concern; the rebound causes rapid bone loss, and while calcium may transiently be released, the primary clinical consequence is fracture. Option C — osteonecrosis of the jaw — is a risk associated with ongoing denosumab use, not discontinuation. Option D — esophageal erosions — is associated with oral bisphosphonates, not denosumab.
Internal links
Throughout this article, the following pages provide additional depth on related clinical topics:
- Electrolyte imbalances nursing — calcium and phosphate homeostasis, hypocalcemia and hypercalcemia mnemonics
- Nursing lab values cheat sheet — complete reference ranges for labs discussed in the osteoporosis workup
- DVT nursing — DVT risk stratification, prophylaxis, and treatment, relevant to hip fracture management
- Head-to-toe nursing assessment — systematic assessment framework applicable to neurovascular checks and fall risk evaluation
- Medication rights in nursing — medication safety principles for administering bisphosphonates, denosumab, and teriparatide